Free Trial

Oncolytics Biotech (TSE:ONC) Shares Up 24.1% - Here's What Happened

Oncolytics Biotech logo with Medical background

Shares of Oncolytics Biotech Inc. (TSE:ONC - Get Free Report) traded up 24.1% during trading on Wednesday . The company traded as high as C$1.72 and last traded at C$1.70. 892,106 shares changed hands during trading, an increase of 556% from the average session volume of 135,968 shares. The stock had previously closed at C$1.37.

Wall Street Analysts Forecast Growth

Separately, Jones Trading lowered Oncolytics Biotech from a "strong-buy" rating to a "hold" rating in a research note on Friday, May 16th.

Get Our Latest Research Report on Oncolytics Biotech

Oncolytics Biotech Stock Performance

The company has a quick ratio of 8.86, a current ratio of 2.99 and a debt-to-equity ratio of 11.75. The company has a 50-day simple moving average of C$0.82 and a two-hundred day simple moving average of C$0.94. The firm has a market cap of C$123.32 million, a PE ratio of -4.46 and a beta of 1.35.

About Oncolytics Biotech

(Get Free Report)

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.

Further Reading

Should You Invest $1,000 in Oncolytics Biotech Right Now?

Before you consider Oncolytics Biotech, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncolytics Biotech wasn't on the list.

While Oncolytics Biotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Watch Before Monday: Stocks to Load Up on Before Earnings
3 Hot Growth Stocks to Watch Right Now!
Don’t Miss These Top 3 Defense Stocks Set To Gain

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines